Provided by Tiger Trade Technology Pte. Ltd.

CytomX Therapeutics

3.28
-0.0100-0.30%
Pre-market: 3.27-0.0100-0.30%07:34 EDT
Volume:2.89M
Turnover:9.61M
Market Cap:714.07M
PE:-7.21
High:3.42
Open:3.31
Low:3.27
Close:3.29
52wk High:8.21
52wk Low:1.90
Shares:217.70M
Float Shares:180.00M
Volume Ratio:1.08
T/O Rate:1.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4548
EPS(LYR):-0.1500
ROE:-37.75%
ROA:-19.58%
PB:2.36
PE(LYR):-21.87

Loading ...

CytomX Therapeutics upgraded to Overweight from Neutral at JPMorgan

TIPRANKS
·
Mar 16

CytomX Therapeutics Inc : JP Morgan Raises to Overweight From Neutral; Raises Target Price to $12 From $7

THOMSON REUTERS
·
Mar 16

Wedbush Adjusts Price Target on CytomX Therapeutics to $11 From $6, Maintains Outperform Rating

MT Newswires Live
·
Mar 16

Nebius Group, CytomX Therapeutics, National Storage Affiliates Trust And Other Big Stocks Moving Higher On Monday

Benzinga_recent_news
·
Mar 16

CytomX Therapeutics price target raised to $12 from $10 at Oppenheimer

TIPRANKS
·
Mar 16

Sector Update: Health Care

MT Newswires Live
·
Mar 16

CytomX Therapeutics Details Phase 1 Trial Results For Colorectal Cancer Treatment

MT Newswires Live
·
Mar 16

BRIEF-Cytomx’S Varsetatug Masetecan (Epcam Probody® Adc) Continues To Demonstrate Positive Data Supporting Potential As A New Treatment Option In Late-Line Colorectal Cancer

Reuters
·
Mar 16

CytomX Therapeutics reports Q4 EPS (22c), consensus (9c)

TIPRANKS
·
Mar 16

Earnings Flash (CTMX) CytomX Therapeutics Posts 2025 Loss $0.15 a Share, vs. FactSet Est of $0.03 Loss

MT Newswires Live
·
Mar 16

CytomX Therapeutics Inc - Phase 1 Study With Bevacizumab Initiated; Phase 1B/2 Chemotherapy Combination Study to Start by End 2026

THOMSON REUTERS
·
Mar 16

CytomX’s Varsetatug Masetecan (Epcam Probody® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

THOMSON REUTERS
·
Mar 16

CytomX Therapeutics Q4 EPS $(0.22) Misses $(0.09) Estimate, Sales $663.000K Miss $7.900M Estimate

Benzinga Earnings
·
Mar 16

BRIEF-CytomX Therapeutics FY Revenue USD 76.201 Million Vs. IBES Estimate USD 83.5 Million

Reuters
·
Mar 16

CytomX reports FY2025 revenue of USD 76.2 million and cash of USD 137.1 million

Reuters
·
Mar 16

CytomX Therapeutics FY Net Income USD -17.368 Million

THOMSON REUTERS
·
Mar 16

CytomX reports 32% ORR for varsetatug masetecan in Phase 1 late-line metastatic colorectal cancer study

Reuters
·
Mar 16

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 16

U.S. Earnings Preview: Before Market Open March 16

Dow Jones
·
Mar 16

CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga
·
Mar 16